Taking A Bold Path To Improve Fibrosis Prognosis
Agomab Is Targeting Two Growth Factor Pathways Which Could Help To Modify Disease Outcomes
Tim Knotnerus is empowering Agomab’s team to investigate the potential of growth factor pathways across four different fibrotic indications.
You may also be interested in...
BioFactura has completed a successful Phase I trial of its Stelara (ustekinumab) biosimilar BFI-751, which is expected to file in developed markets in 2026.
Generics industry trade group Medicines for Europe has met with Ukrainian government officials to discuss how to plan for any future integration process.
Adcock saw its profits grow by 4.2% during FY 2024 despite a challenging economic environment.